Can Radiomics Predict Survival in Patients With NSCLC Receiving Immunotherapy? – The ASCO Post
Immunotherapy with immune checkpoint inhibitors has made great strides in the treatment of many cancers, but only between 25% and 50% of patients respond with clinical benefit, and these agents come with adverse events and high price tags. Thus, preselection of patients who are likely to respond to this type of therapy…